


Ticlopidine-d4 hydrochloride

Cat. No.:	HY-B0153AS
Molecular Formula:	C ₁₄ H ₁₁ D ₄ Cl ₂ NS
Molecular Weight:	304.27
Target:	Adenosine Receptor
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Ticlopidine-d4 hydrochloride is the deuterium labeled Ticlopidine hydrochloride. Ticlopidine hydrochloride is an adenosine diphosphate (ADP) receptor inhibitor against platelet aggregation with IC ₅₀ of ~2 μM.
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.
- [2]. Thebault JJ, et al. Effects of ticlopidine, a new platelet aggregation inhibitor in man. *Clin Pharmacol Ther.* 1975 Oct;18(4):485-90.
- [3]. Ashida SI, et al. Mode of action of ticlopidine in inhibition of platelet aggregation in the rat. *Thromb Haemost.* 1979 Apr 23;41(2):436-49.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA